- Seres Therapeutics Inc (NASDAQ: MCRB) and its study partners have voluntarily discontinued further enrollment in the Phase 1 study evaluating SER-401 in metastatic melanoma.
- The company cited challenges related to the pandemic.
- The study was assessing the safety and drug activity of SER-401 or fecal microbiota transplant (FMT) in combination with nivolumab.
- A preliminary analysis of results from 10 subjects indicated that SER-401 was safe and well-tolerated.
- No patients were enrolled in the FMT portion of the study.
- Subjects currently enrolled in the study will complete the study protocol.
- Price Action: MCRB shares gained 0.73% at $19.2 in premarket trading on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
